Abstracts tagged "rheumatoid arthritis (RA) and statistical methods"

Abstract Number: 2903 • 2018 ACR/ARHP Annual Meeting
Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis
Chamith Fonseka¹, Deepak Rao², Nikola Teslovich³, Ilya Korsunsky⁴, Susan Hannes⁵, Kamil Slowikowski¹, Michael Gurish⁶, Laura T. Donlin⁷, James A. Lederer⁸, Michael Weinblatt⁹, Elena Massarotti⁹, Jonathan Coblyn⁹, Simon Helfgott¹⁰, Derrick J. Todd¹¹, Vivian P. Bykerk¹², Elizabeth Karlson¹³, Joerg Ermann¹⁴, Yvonne C. Lee¹⁵, Michael Brenner¹⁶ and Soumya Raychaudhuri^1,17, ¹Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Human Immunology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Genetics and Rheumatology, Department of Medicine, Harvard Medical School, Boston, MA, ⁴Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁸Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁶Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁷Program in Medical and Population Genetics, Broad Institute, Boston, MA
Background/Purpose: Defining the precise CD4+ T cell subsets that are dysregulated in RA patients is critical to deciphering pathogenesis. Here we present Mixed effects modeling…
Abstract Number: 126 • 2017 ACR/ARHP Annual Meeting
Smoking Is Causally Associated with Disease Activity in Rheumatoid Arthritis
Milena Gianfrancesco¹, Laura Trupin², Stephen Shiboski³, Mark van der Laan⁴, Jonathan Graf⁵, John B. Imboden Jr.⁶, Jinoos Yazdany² and Gabriela Schmajuk⁷, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴University of California, Berkeley, Berkeley, CA, ⁵Department of Medicine, Division of Rheumatology Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, ⁶Medicine, University of California, San Francisco, San Francisco, CA, ⁷San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA
Background/Purpose: The association between smoking and risk of rheumatoid arthritis (RA) has been well documented; however, the relationship between smoking and RA disease activity is…
Abstract Number: 2540 • 2016 ACR/ARHP Annual Meeting
The Longitudinal Impact of Biologic Use on Disability within a RA Registry
N A Shadick¹, Nicole Gerlanc², M Frits¹, Bradley S. Stolshek³, Brenna Brady², Christine Iannaccone⁴, David Collier⁵, Jing Cui⁶, Alex Mutebi⁷ and Michael Weinblatt⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Health Analytics, LLC, Columbia, MD, ³Amgen, Thousand Oaks, CA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Global Health Economics, Amgen, Thousand Oaks, CA
Background/Purpose: Biologics have become the standard of care for treating moderate to severe rheumatoid arthritis (RA) in patients with an inadequate response to small molecule…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].